Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free KLRA Stock Alerts

Kailera Therapeutics (KLRA) Competitors

Kailera Therapeutics logo
$18.59 -0.28 (-1.48%)
As of 04:00 PM Eastern
Compare

KLRA vs. SYRE, IONS, PRAX, KYMR, and APGE

Should you buy Kailera Therapeutics stock or one of its competitors? Kailera Therapeutics's main competitors and comparable companies include Spyre Therapeutics (SYRE), Ionis Pharmaceuticals (IONS), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), and Apogee Therapeutics (APGE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kailera Therapeutics compare to Spyre Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Kailera Therapeutics currently has a consensus price target of $42.75, suggesting a potential upside of 129.96%. Spyre Therapeutics has a consensus price target of $111.69, suggesting a potential upside of 7.30%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kailera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87

Kailera Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kailera TherapeuticsN/A N/A N/A
Spyre Therapeutics N/A -30.74%-22.23%

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kailera TherapeuticsN/AN/A-$148.96M-$3.65 thousandN/A
Spyre TherapeuticsN/AN/A-$155.20M-$1.95N/A

In the previous week, Spyre Therapeutics had 20 more articles in the media than Kailera Therapeutics. MarketBeat recorded 24 mentions for Spyre Therapeutics and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat Spyre Therapeutics' score of 0.54 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kailera Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Spyre Therapeutics
9 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Kailera Therapeutics beats Spyre Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Kailera Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Kailera Therapeutics has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$944M9.95-$381.39M-$3.46N/A
Kailera TherapeuticsN/AN/A-$148.96M-$3.65 thousandN/A

Kailera Therapeutics has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Kailera Therapeutics' return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-64.76% -111.08% -17.41%
Kailera Therapeutics N/A N/A N/A

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Ionis Pharmaceuticals had 5 more articles in the media than Kailera Therapeutics. MarketBeat recorded 9 mentions for Ionis Pharmaceuticals and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat Ionis Pharmaceuticals' score of 0.05 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Kailera Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ionis Pharmaceuticals currently has a consensus target price of $94.65, indicating a potential upside of 67.43%. Kailera Therapeutics has a consensus target price of $42.75, indicating a potential upside of 129.96%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kailera Therapeutics is more favorable than Ionis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77
Kailera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Kailera Therapeutics beats Ionis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Kailera Therapeutics compare to Praxis Precision Medicines?

Kailera Therapeutics (NASDAQ:KLRA) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Praxis Precision Medicines had 31 more articles in the media than Kailera Therapeutics. MarketBeat recorded 35 mentions for Praxis Precision Medicines and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat Praxis Precision Medicines' score of 0.77 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kailera Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Praxis Precision Medicines
7 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kailera TherapeuticsN/AN/A-$148.96M-$3.65 thousandN/A
Praxis Precision MedicinesN/AN/A-$303.27M-$12.93N/A

Kailera Therapeutics currently has a consensus price target of $42.75, suggesting a potential upside of 129.96%. Praxis Precision Medicines has a consensus price target of $573.05, suggesting a potential upside of 48.33%. Given Kailera Therapeutics' higher probable upside, equities research analysts plainly believe Kailera Therapeutics is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kailera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Praxis Precision Medicines
2 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
4 Strong Buy rating(s)
3.00

Kailera Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Kailera TherapeuticsN/A N/A N/A
Praxis Precision Medicines N/A -34.15%-32.42%

Summary

Praxis Precision Medicines beats Kailera Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Kailera Therapeutics compare to Kymera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Kailera Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kailera Therapeutics' return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kailera TherapeuticsN/A N/A N/A
Kymera Therapeutics -285.33%-21.22%-19.21%

In the previous week, Kymera Therapeutics had 19 more articles in the media than Kailera Therapeutics. MarketBeat recorded 23 mentions for Kymera Therapeutics and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat Kymera Therapeutics' score of -0.22 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kailera Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

Kailera Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kailera TherapeuticsN/AN/A-$148.96M-$3.65 thousandN/A
Kymera Therapeutics$39.21M241.82-$311.35M-$3.24N/A

Kailera Therapeutics presently has a consensus target price of $42.75, suggesting a potential upside of 129.96%. Kymera Therapeutics has a consensus target price of $125.65, suggesting a potential upside of 10.19%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kailera Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kailera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
20 Buy rating(s)
0 Strong Buy rating(s)
2.83

Summary

Kailera Therapeutics beats Kymera Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Kailera Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apogee TherapeuticsN/AN/A-$255.84M-$4.34N/A
Kailera TherapeuticsN/AN/A-$148.96M-$3.65 thousandN/A

Kailera Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Apogee TherapeuticsN/A -32.16% -30.91%
Kailera Therapeutics N/A N/A N/A

In the previous week, Apogee Therapeutics had 12 more articles in the media than Kailera Therapeutics. MarketBeat recorded 16 mentions for Apogee Therapeutics and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.85 beat Apogee Therapeutics' score of 0.62 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apogee Therapeutics
6 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Kailera Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Apogee Therapeutics presently has a consensus price target of $121.25, indicating a potential downside of 9.88%. Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 129.96%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Apogee Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apogee Therapeutics
1 Sell rating(s)
16 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.19
Kailera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Kailera Therapeutics beats Apogee Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Kailera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KLRA vs. The Competition

Export
MetricKailera TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.44B$3.73B$7.04B$12.94B
Dividend YieldN/A3.76%2.58%10.33%
P/E RatioN/A10.41268.8325.29
Price / SalesN/A1,277.82590.3479.66
Price / CashN/A102.5472.2650.42
Price / BookN/A17.9013.166.23
Net Income-$148.96M-$13.23M$3.45B$347.40M
7 Day Performance2.31%3.55%2.02%1.46%
1 Month Performance-10.11%-0.71%-0.23%-0.49%
1 Year PerformanceN/A60.44%70.60%20.91%

Kailera Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KLRA
Kailera Therapeutics
1.7561 of 5 stars		$18.59
-1.5%		$42.75
+130.0%		N/A$2.44BN/AN/A145
SYRE
Spyre Therapeutics
1.7243 of 5 stars		$98.33
-3.1%		$101.42
+3.1%		+573.7%$8.65B$890KN/A73
IONS
Ionis Pharmaceuticals
3.0381 of 5 stars		$51.77
-2.8%		$94.85
+83.2%		+35.7%$8.60B$944MN/A1,402
PRAX
Praxis Precision Medicines
3.2552 of 5 stars		$307.83
+0.0%		$563.50
+83.1%		+724.6%$8.58B$8.55MN/A110
KYMR
Kymera Therapeutics
1.1457 of 5 stars		$103.40
-3.4%		$124.48
+20.4%		+190.9%$8.51B$39.21MN/A170

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KLRA) was last updated on 8/12/2026 by MarketBeat.com Staff.
From Our Partners
Iran War: What Happened at 1:11 P.M. Outside D.C.?
A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...
Banyan Hill Publishing | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
The government values gold at $42. It's really $4,800.
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
A $2 trillion fund just sounded the alarm
Norway's roughly $2 trillion sovereign wealth fund holds massive stakes in Nvidia, Apple and SpaceX. Its CEO n...
The Oxford Club | Sponsoredtc pixel